Literature DB >> 2409201

Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies.

R C Kennedy, G R Dreesman, J S Butel, R E Lanford.   

Abstract

This study characterizes four private idiotypes (Id) associated with monoclonal antibodies (mAb) to simian virus 40 (SV40) tumor antigen (T-Ag), and to a cellular protein, p53. Anti-Id recognized Id determinants associated with the antibody-combining site. BALB/c mice receiving a pool of anti-Id directed against mAb recognizing distinct amino and carboxyl terminal epitopes of T-Ag before receiving a tumorigenic dose of SV40-transformed cells showed suppression of tumor formation. Serum obtained from these mice before tumor challenge contained anti-anti-Id that failed to bind T-Ag. These data support the potential role of regulatory idiotopes in tumor immunity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409201      PMCID: PMC2187644          DOI: 10.1084/jem.161.6.1432

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  65 in total

1.  Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts.

Authors:  S Fujimoto; M I Greene; A H Sehon
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

2.  Nuclear preparations of SV40-transformed cells contain tumor-specific transplantation antigen activity.

Authors:  J L Anderson; R G Martin; C Chang; P T Mora; D M Livingston
Journal:  Virology       Date:  1977-01       Impact factor: 3.616

3.  Activation of suppressor T cells by tumour cells and specific antibody.

Authors:  R K Gershon; M B Mokyr; M S Mitchell
Journal:  Nature       Date:  1974-08-16       Impact factor: 49.962

4.  Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. I. Development of cellular immunity to simian virus 40 tumor-specific transplantation antigens during tumorigenesis by transplanted cells.

Authors:  J M Zarling; S S Tevethia
Journal:  J Natl Cancer Inst       Date:  1973-01       Impact factor: 13.506

5.  Transplantable mouse tumor line induced by injection of SV40-transformed mouse kidney cells.

Authors:  S Kit; T Kurimura; D R Dubbs
Journal:  Int J Cancer       Date:  1969-07-15       Impact factor: 7.396

6.  Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy.

Authors:  M J Daley; H M Gebel; R G Lynch
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

7.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

8.  Myeloma proteins as tumor-specific transplantation antigens.

Authors:  R G Lynch; R J Graff; S Sirisinha; E S Simms; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

9.  Variation in properties of plaque progeny of PARA (defective simian papovavirus 40)-adenovirus 7.

Authors:  F Rapp; S Pauluzzi; J S Butel
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

10.  Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice.

Authors:  S Sugai; D W Palmer; N Talal; I P Witz
Journal:  J Exp Med       Date:  1974-12-01       Impact factor: 14.307

View more
  13 in total

1.  Polyclonal anti-idiotypic antibodies mimicking the small cell lung carcinoma antigen cluster-5A interact with a panel of antibodies and induce specific immune response in animals.

Authors:  C Zwicky; R A Stahel; H Jaksche; R Waibel; H P Lehmann; H Loibner
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen.

Authors:  R L Mernaugh; M H Shearer; R K Bright; R E Lanford; R C Kennedy
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Possible role of anti-idiotypic antibodies in the induction of tumor immunity.

Authors:  R C Kennedy; E M Zhou; R E Lanford; T C Chanh; C A Bona
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

Review 4.  Anti-idiotypic antibodies and the induction of specific tumor immunity.

Authors:  G T Nepom; K E Hellström
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 5.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; A Chen; M L Nguyen; H Yoshiyama; W J Morrow; D D Ho; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

7.  Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge.

Authors:  P L Dunn; C A Johnson; J M Styles; S S Pease; C J Dean
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

8.  Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine.

Authors:  K A Foon; M Chakraborty; W J John; A Sherratt; H Köhler; M Bhattacharya-Chatterjee
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

Authors:  C D Estin; U S Stevenson; G D Plowman; S L Hu; P Sridhar; I Hellström; J P Brown; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

10.  Monoclonal anti-idiotypic antibody mimics the CD4 receptor and binds human immunodeficiency virus.

Authors:  T C Chanh; G R Dreesman; R C Kennedy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.